Latest topics page 35

Topics ordered by most recent activity across all 71 subcategories.

1,535 topics · page 35 of 52

Topic	Participants	Replies	Views	Activity
[2026 update] A certificate with no method stated: what can you conclude? Analytics › COA interpretation reference standards certificate of analysis documentation quality batch & lot numbers Solved A certificate with no method stated: what can you conclude? — that is the question, and I have not found it answered plainly anywhere I have looked. I would like to understand what this number means before I…		2	82	11mo
When a preprint is the best available evidence and we say so Evidence › Preprints risk of bias effect size preprint Solved When a preprint is the best available evidence and we say so — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in…	+148	160	31k	11mo
Coming back to: Sample size calculations, read backwards from the published number Evidence › Trials estimand discontinuation & dropout surrogate endpoints randomised trial On the subject in the title: Sample size calculations, read backwards from the published number Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…	+82	88	1.8k	11mo
Why a pen's dose steps are fixed and what that costs you — one year on Devices › Pens & autoinjectors storage subcutaneous injection missed dose Solved Closed Asking directly, because I could not find a straight answer: Why a pen's dose steps are fixed and what that costs you — one year on I have read the maintained page on this and I still have a gap, so I am…	+30	34	2.9k	11mo
[2026 update] What we do not know about retatrutide, listed explicitly Compounds › Retatrutide TRIUMPH programme preprint effect size randomised trial Wiki What we do not know about retatrutide, listed explicitly — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SCALE ( N Engl J Med , 2015) with STEP 2 ( Lancet ,…	+79	83	952	11mo
Tag proliferation and whether we should prune Meta › Site feedback guidelines site feedback moderation Closed On the subject in the title: Tag proliferation and whether we should prune Working notes rather than a conclusion. Process question about how this site works. I have read the guidelines and the trust-level…		2	11k	11mo
Journal club: STEP-HFpEF and symptom endpoints Evidence › Journal club journal club effect size estimand risk of bias Journal club: STEP-HFpEF and symptom endpoints — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURMOUNT-1 ( N Engl J Med , 2022) and finding…	+18	22	2.5k	11mo
Revisiting: Filter needles: when they help and what they cost you Devices › Syringes & needles worked example needle gauge & length subcutaneous injection dead volume Closed Revisiting: Filter needles: when they help and what they cost you — setting out what I have, and where I think it stops being reliable. A question about technique rather than about dose. I have been doing the…	+48	52	6.6k	11mo
An emergency department visit, described afterwards Safety › Adverse events gallbladder hypoglycaemia pancreatitis An emergency department visit, described afterwards Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The published…	+56	62	1.4k	11mo
The CagriSema phase 2 paper and what a fixed combination buys Compounds › Cagrilintide & amylin analogues randomised trial cagrilintide effect size Posting this under the heading it deserves: The CagriSema phase 2 paper and what a fixed combination buys Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in…	+88	93	29k	11mo
SURMOUNT-4 and what withdrawal data does and does not tell an individual Compounds › Tirzepatide SURPASS programme randomised trial effect size SURMOUNT programme Solved SURMOUNT-4 and what withdrawal data does and does not tell an individual — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 8 ( JAMA , 2022)…		4	42k	11mo
Asking about a compound your prescriber has not heard of Clinical › Prescriber conversations telehealth prior authorisation beginner friendly Asking about a compound your prescriber has not heard of Writing it up because I had to work it out twice and would rather nobody else did. General question, not a request for advice about my own care — I…	+137	148	15k	11mo
Risk-of-bias tools and the judgement they conceal Evidence › Meta-analyses meta-analysis heterogeneity publication bias effect size Wiki Risk-of-bias tools and the judgement they conceal Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in support of a claim I do…	+8	12	21k	11mo
Are there stupid questions here? A staff answer, at length Start Here › Welcome beginner friendly guidelines onboarding trust levels Solved Are there stupid questions here? A staff answer, at length I have a specific reason for asking rather than idle curiosity, and the context is below. Question in the title. Context below, and I have tried to…	+122	153	50k	11mo
Appeal templates and why they are deliberately unemotional — one year on Access › Insurance & coverage insurance appeals prior authorisation formulary Closed Appeal templates and why they are deliberately unemotional — one year on Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because…		2	4.1k	11mo
Second pass at: Why this subcategory is stricter about sourcing than most Compounds › Secretagogues & GH axis observational data ipamorelin tesamorelin needs a source Second pass at: Why this subcategory is stricter about sourcing than most — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SURMOUNT-4 ( JAMA ,…	+120	129	61k	11mo
Criticising the method without criticising the authors — one year on Evidence › Study critique confounding effect size disputed risk of bias Solved Closed On the subject in the title: Criticising the method without criticising the authors — one year on Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting;…	+16	20	61k	11mo
Vagal afferents and the gut-brain pathway — one year on Pharmacology › Receptor biology amylin analogues long read semaglutide retatrutide Vagal afferents and the gut-brain pathway — one year on Writing it up because I had to work it out twice and would rather nobody else did. A documentation question rather than an analytical one. I have a…		2	136	11mo
Confounding by indication, explained with a concrete example Evidence › Study critique confounding observational data disputed On the subject in the title: Confounding by indication, explained with a concrete example Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SURPASS-2 ( N Engl J Med ,…	+21	25	21k	11mo
Follow-up: What is genuinely unknown about long-term amylin agonism Compounds › Cagrilintide & amylin analogues effect size amylin analogues cagrisema What is genuinely unknown about long-term amylin agonism I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in support…		2	25k	11mo
System suitability injections: if they failed, the run did not happen Analytics › HPLC & UHPLC peak integration HPLC data table gradient method Posting this under the heading it deserves: System suitability injections: if they failed, the run did not happen Everything below is what sits behind that. A documentation question rather than an analytical…	+23	27	6k	11mo
A friction point in the promotion workflow Meta › Site feedback guidelines moderation site feedback A friction point in the promotion workflow — setting out what I have, and where I think it stops being reliable. Nominating something for promotion into the documentation commons. The topic in question keeps…	+4	8	491	11mo
MALDI versus ESI for a quick identity check Analytics › Mass spectrometry high-resolution MS charge states mass error (ppm) MALDI-TOF Closed On the subject in the title: MALDI versus ESI for a quick identity check Working notes rather than a conclusion. Working through the identity arithmetic and I would like it checked. tirzepatide has a…		2	2k	11mo
Distinguishing a deletion sequence by mass alone — the long version Analytics › Mass spectrometry high-resolution MS mass error (ppm) charge states MALDI-TOF On the subject in the title: Distinguishing a deletion sequence by mass alone — the long version Working notes rather than a conclusion. I would like to understand what this number means before I repeat it…	+38	44	60k	11mo
Coming back to: Checking someone else's arithmetic: a worked example thread Practice › Reconstitution concentration maths reconstitution bacteriostatic water dead volume Posting this under the heading it deserves: Checking someone else's arithmetic: a worked example thread Everything below is what sits behind that. Practical question with the units stated, because I have seen…	+13	17	293	11mo
When a tidy document is a signal and when it is decoration — does this still hold? Analytics › COA interpretation reference standards amino acid analysis documentation quality certificate of analysis Solved Asking directly, because I could not find a straight answer: When a tidy document is a signal and when it is decoration — does this still hold? A documentation question rather than an analytical one. I have a…	+3	7	22k	11mo
Enforcement priorities versus written rules — does this still hold? Sourcing › Regulatory EMA MHRA compounding FDA Solved Under review Enforcement priorities versus written rules — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Structured report rather than an opinion, following…	+36	40	37k	11mo
EU-wide position versus national implementation Regional › European Union EMA personal import cost per milligram formulary Solved Under review EU-wide position versus national implementation Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this category…	+22	29	356	11mo
Immortal time bias in a claims-database study Evidence › Study critique risk of bias observational data disputed confounding Closed Immortal time bias in a claims-database study — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it…	+29	34	28k	11mo
Comparing the STEP programme populations: who was actually enrolled — the long version Compounds › Semaglutide STEP programme randomised trial type 2 diabetes On the subject in the title: Comparing the STEP programme populations: who was actually enrolled — the long version Working notes rather than a conclusion. Comparing PIONEER 6 ( N Engl J Med , 2019) with…		4	7.7k	11mo

Commons at a glance

1,535Topics

75,165Posts

452Solved

68Documents

829Members

205Logged actions

Established 6 May 2024. Figures are current as of 28 July 2026.

Sponsored Sigma-Aldrich standardsCertified reference materials and analytical reagents for calibration and method work.Browse standards →

Recently maintained

All docs

Liraglutide — referenceUpdated 25 Jul 2026 · reviewed by 8 Mar 2027
Water content by Karl Fischer titrationUpdated 17 Jul 2026 · reviewed by 7 Apr 2027
SURMOUNT-1 — trial digestUpdated 15 Jul 2026 · reviewed by 21 May 2027
CJC-1295 — referenceUpdated 12 Jul 2026 · reviewed by 7 Jan 2027
SURPASS-2 — trial digestUpdated 9 Jul 2026 · reviewed by 1 Sep 2026
LEADER — trial digestUpdated 9 Jul 2026 · reviewed by 27 Mar 2027
PeptideMeter — what its reports establishUpdated 5 Jul 2026 · reviewed by 28 Oct 2026

Busiest tags

All tags

effect size 214randomised trial 174worked example 139data table 117beginner friendly 110documentation quality 102needs a source 90 site feedback 87 risk of bias 83 semaglutide 80 guidelines 78 missed dose 77 fatigue 77 tirzepatide 73 observational data 67 delayed gastric emptying 65 estimand 65 type 2 diabetes 65

Most solutions

Badge

e.ferreira TL25 marked solutions
e.ferreira TL35 marked solutions · Regular
sa.vogel TL24 marked solutions
n.kaufmann TL23 marked solutions
i.beaulieu TL23 marked solutions
r.oyelaran TL23 marked solutions
n.zielinski TL23 marked solutions
k.adeyemi TL23 marked solutions

Latest staff actions

Full log

Topic moved R8owen.brady · 28 Jul 2026 · Insomnia at a dose step: reported experiences —…
Post hidden by flag R12hana.sato · 27 Jul 2026 · What a regulator's shortage notice actually…
Hidden post restored R6mira.patel · 27 Jul 2026 · BPC-157: what the rodent literature actually…
Hidden post restored R1bench_notes · 26 Jul 2026 · What would change my mind about repair peptides: a…
Title edited R7owen.brady · 26 Jul 2026 · Why side effects reset at each escalation and that…

Every action, with the rule cited and a written rationale. Nothing is removed from the log.

Sponsored PeptideMeterPeptide analytics and dated supplier verification records.View records →